NO991192L - Middel for behandling av prostatahypertrofi og prostatakreft - Google Patents

Middel for behandling av prostatahypertrofi og prostatakreft

Info

Publication number: NO991192L
Authority: NO; Norway
Prior art keywords: prostate; treatment; hypertrophy; prostate cancer; cancer
Prior art date: 1996-09-12

Application number

NO991192A

Other languages

English (en)

Other versions

NO991192D0 (no

NO326207B1 (no

Inventor

J Rgen Engel

Thomas Reissmann

Ller-Winzen Hilde Riethm

J Rgen Rawert

Original Assignee

Asta Medica Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-12

Filing date

1999-03-11

Publication date

1999-04-28

1999-03-11 Application filed by Asta Medica Ag filed Critical Asta Medica Ag

1999-03-11 Publication of NO991192D0 publication Critical patent/NO991192D0/no

1999-04-28 Publication of NO991192L publication Critical patent/NO991192L/no

2008-10-20 Publication of NO326207B1 publication Critical patent/NO326207B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO19991192A 1996-09-12 1999-03-11 Anvendelse av forbindelsen Cetrorelix for fremstilling av et middel for behandling av prostatahypertrofi og prostatakreft NO326207B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2599096P	1996-09-12	1996-09-12
US4322897P	1997-04-10	1997-04-10
PCT/EP1997/004740 WO1998010781A1 (en)	1996-09-12	1997-09-01	Means for treating prostate hypertrophy and prostate cancer

Publications (3)

Publication Number	Publication Date
NO991192D0 NO991192D0 (no)	1999-03-11
NO991192L true NO991192L (no)	1999-04-28
NO326207B1 NO326207B1 (no)	2008-10-20

Family

ID=26700570

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19991192A NO326207B1 (no)	1996-09-12	1999-03-11	Anvendelse av forbindelsen Cetrorelix for fremstilling av et middel for behandling av prostatahypertrofi og prostatakreft

Country Status (28)

Country	Link
US (4)	US6054432A (no)
EP (1)	EP0925069B1 (no)
JP (1)	JP2001500500A (no)
KR (1)	KR100546235B1 (no)
CN (1)	CN1126566C (no)
AR (1)	AR009757A1 (no)
AT (1)	ATE370743T1 (no)
AU (1)	AU738306B2 (no)
BR (1)	BR9713197A (no)
CA (1)	CA2215015A1 (no)
CZ (1)	CZ298738B6 (no)
DE (1)	DE69738045T2 (no)
DK (1)	DK0925069T3 (no)
EE (1)	EE04000B1 (no)
ES (1)	ES2289764T3 (no)
HU (1)	HUP0000261A3 (no)
IL (3)	IL128331A0 (no)
IS (1)	IS4978A (no)
MX (1)	MXPA99002420A (no)
NO (1)	NO326207B1 (no)
NZ (1)	NZ334540A (no)
PL (1)	PL193184B1 (no)
PT (1)	PT925069E (no)
RU (1)	RU2215537C2 (no)
SK (1)	SK286174B6 (no)
TR (1)	TR199900556T2 (no)
TW (1)	TWI224002B (no)
WO (1)	WO1998010781A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6828415B2 (en) *	1993-02-19	2004-12-07	Zentaris Gmbh	Oligopeptide lyophilisate, their preparation and use
US6054432A (en) *	1996-09-12	2000-04-25	Asta Medica Aktiengesellschaft	Means for treating prostate hypertrophy and prostate cancer
FR2768055A1 (fr) *	1997-09-11	1999-03-12	Synthelabo	Utilisation de derives de sulfonanilide pour obtenir un medicament destine au traitement de l'ejaculation retrograde ou de l'aspermie
TW536402B (en) *	1998-06-26	2003-06-11	Yamanouchi Pharma Co Ltd	Pharmaceutical composition for the therapy of voiding dysfunction
DE19911771B4 (de) *	1999-03-17	2006-03-30	Zentaris Gmbh	LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US7129262B2 (en) *	1999-07-23	2006-10-31	The Regents Of The University Of California	Indole compounds useful for the treatment of cancer
US7361680B2 (en) *	1999-07-23	2008-04-22	The Regents Of The University Of California	Indole compounds useful for the treatment of cancer
US7105560B1 (en)	1999-07-23	2006-09-12	The Regents Of The University Of California	Use of etodolac in the treatment of multiple myeloma
US6545034B1 (en) *	1999-07-23	2003-04-08	The Regents Of The University Of California	Use of etodolac for the treatment of chronic lymphocytic leukemia
US7151100B1 (en)	1999-07-23	2006-12-19	The Regents Of The University Of California	Indole compounds useful for the treatment of cancer
EP1203582A4 (en) *	1999-08-09	2005-08-03	Yamanouchi Pharma Co Ltd	MEDICINAL COMPOSITIONS FOR THE TREATMENT OF LOWER UROPATHY
CA2669753C (en)	1999-09-30	2012-06-26	Hollis-Eden Pharmaceuticals, Inc.	Therapeutic treatment of androgen receptor driven conditions
US20040152672A1 (en) *	2000-08-09	2004-08-05	Carson Dennis A.	Indole compounds useful for the treatment of cancer
KR100876538B1 (ko) *	2000-08-17	2008-12-31	아에테르나 젠타리스 게엠베하	Ｌｈｒｈ 길항제의 염의 제조방법
DE10040700A1 (de) *	2000-08-17	2002-02-28	Asta Medica Ag	Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
JP2001288115A (ja) *	2001-02-07	2001-10-16	Yamanouchi Pharmaceut Co Ltd	下部尿路症治療剤
DE10137174A1 (de) *	2001-07-31	2003-02-13	Zentaris Ag	Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
WO2004026116A2 (en) *	2002-09-19	2004-04-01	The Regents Of The University Of California	Use of etodoclac to treat hyperplasia
GB0301016D0 (en) *	2003-01-16	2003-02-19	Univ London	Treatment of benign prostatic hyperplasia
WO2004064736A2 (en)	2003-01-17	2004-08-05	Threshold Pharmaceuticals, Inc.	Treatment of benign prostatic hyperplasia using energolytic agents
AU2007248533B2 (en) *	2006-05-03	2012-03-15	Wisconsin Alumni Research Foundation	NL, N4-bis (buta-1, 3-dienyl) butane-1, 4-diamine pharmaceutical compositions and uses thereof
EP1891964A1 (en) *	2006-08-08	2008-02-27	AEterna Zentaris GmbH	Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) *	2007-03-05	2008-09-10	AEterna Zentaris GmbH	Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
EP2095818A1 (en) *	2008-02-29	2009-09-02	AEterna Zentaris GmbH	Use of LHRH antagonists at non-castrating doses
US10585101B2 (en)	2016-03-10	2020-03-10	Wavesense, Inc.	Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2465486A1 (fr) *	1979-09-21	1981-03-27	Roussel Uclaf	Nouvelle application utilisant la lh-rh ou des agonistes
HU199694B (en) *	1988-05-10	1990-03-28	Innofinance Altalanos Innovaci	Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives
DE3918543A1 (de) *	1989-06-07	1990-12-13	Boehringer Mannheim Gmbh	Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie
NZ241979A (en) *	1991-03-20	1996-01-26	Merck & Co Inc	Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
IL101245A0 (en) *	1991-03-20	1992-11-15	Merck & Co Inc	Pharmaceutical compositions for the treatment of prostatic cancer
US6054432A (en) *	1996-09-12	2000-04-25	Asta Medica Aktiengesellschaft	Means for treating prostate hypertrophy and prostate cancer

1997
- 1997-08-07 US US08/908,198 patent/US6054432A/en not_active Expired - Fee Related
- 1997-09-01 AT AT97944818T patent/ATE370743T1/de not_active IP Right Cessation
- 1997-09-01 WO PCT/EP1997/004740 patent/WO1998010781A1/en not_active Ceased
- 1997-09-01 KR KR1019997002053A patent/KR100546235B1/ko not_active Expired - Lifetime
- 1997-09-01 AU AU46198/97A patent/AU738306B2/en not_active Ceased
- 1997-09-01 EP EP97944818A patent/EP0925069B1/en not_active Expired - Lifetime
- 1997-09-01 IL IL12833197A patent/IL128331A0/xx unknown
- 1997-09-01 SK SK301-99A patent/SK286174B6/sk not_active IP Right Cessation
- 1997-09-01 DE DE69738045T patent/DE69738045T2/de not_active Expired - Lifetime
- 1997-09-01 PT PT97944818T patent/PT925069E/pt unknown
- 1997-09-01 CN CN97197904A patent/CN1126566C/zh not_active Expired - Fee Related
- 1997-09-01 DK DK97944818T patent/DK0925069T3/da active
- 1997-09-01 RU RU99107280/14A patent/RU2215537C2/ru not_active IP Right Cessation
- 1997-09-01 JP JP10513204A patent/JP2001500500A/ja active Pending
- 1997-09-01 MX MXPA99002420A patent/MXPA99002420A/es unknown
- 1997-09-01 TR TR1999/00556T patent/TR199900556T2/xx unknown
- 1997-09-01 HU HU0000261A patent/HUP0000261A3/hu unknown
- 1997-09-01 EE EEP199900121A patent/EE04000B1/xx not_active IP Right Cessation
- 1997-09-01 BR BR9713197-0A patent/BR9713197A/pt not_active Application Discontinuation
- 1997-09-01 NZ NZ334540A patent/NZ334540A/xx unknown
- 1997-09-01 CZ CZ80899A patent/CZ298738B6/cs not_active IP Right Cessation
- 1997-09-01 ES ES97944818T patent/ES2289764T3/es not_active Expired - Lifetime
- 1997-09-01 PL PL332085A patent/PL193184B1/pl not_active IP Right Cessation
- 1997-09-10 TW TW086113121A patent/TWI224002B/zh active
- 1997-09-10 CA CA002215015A patent/CA2215015A1/en not_active Abandoned
- 1997-09-11 AR ARP970104168A patent/AR009757A1/es not_active Application Discontinuation
1998
- 1998-04-09 US US09/057,458 patent/US5998377A/en not_active Expired - Fee Related
- 1998-04-20 US US09/062,704 patent/US6071882A/en not_active Expired - Fee Related
1999
- 1999-02-02 IL IL128331A patent/IL128331A/en not_active IP Right Cessation
- 1999-02-16 IS IS4978A patent/IS4978A/is unknown
- 1999-03-11 NO NO19991192A patent/NO326207B1/no not_active IP Right Cessation
- 1999-09-22 US US09/401,851 patent/US6300313B1/en not_active Expired - Fee Related
2008
- 2008-01-30 IL IL189132A patent/IL189132A0/en unknown

Also Published As

Publication number	Publication date
MXPA99002420A (es)	2004-08-27
EE04000B1 (et)	2003-04-15
IL128331A0 (en)	2000-01-31
IL128331A (en)	2010-05-31
AU738306B2 (en)	2001-09-13
ATE370743T1 (de)	2007-09-15
KR20010029495A (ko)	2001-04-06
AR009757A1 (es)	2000-05-03
NO991192D0 (no)	1999-03-11
US5998377A (en)	1999-12-07
IS4978A (is)	1999-02-16
TWI224002B (en)	2004-11-21
DE69738045T2 (de)	2008-05-15
CA2215015A1 (en)	1998-03-12
US6054432A (en)	2000-04-25
DK0925069T3 (da)	2007-10-29
ES2289764T3 (es)	2008-02-01
HK1021937A1 (en)	2000-07-21
US6300313B1 (en)	2001-10-09
SK286174B6 (sk)	2008-04-07
HUP0000261A2 (hu)	2000-10-28
NZ334540A (en)	2000-07-28
PT925069E (pt)	2007-10-17
IL189132A0 (en)	2008-06-05
JP2001500500A (ja)	2001-01-16
NO326207B1 (no)	2008-10-20
CZ80899A3 (cs)	1999-11-17
AU4619897A (en)	1998-04-02
TR199900556T2 (xx)	1999-07-21
EE9900121A (et)	1999-10-15
CZ298738B6 (cs)	2008-01-09
CN1230121A (zh)	1999-09-29
RU2215537C2 (ru)	2003-11-10
EP0925069B1 (en)	2007-08-22
SK30199A3 (en)	2000-03-13
PL193184B1 (pl)	2007-01-31
US6071882A (en)	2000-06-06
EP0925069A1 (en)	1999-06-30
WO1998010781A1 (en)	1998-03-19
DE69738045D1 (de)	2007-10-04
PL332085A1 (en)	1999-08-30
BR9713197A (pt)	2000-04-04
CN1126566C (zh)	2003-11-05
HUP0000261A3 (en)	2001-03-28
KR100546235B1 (ko)	2006-01-26

Publication	Publication Date	Title
NO991192L (no)	1999-04-28	Middel for behandling av prostatahypertrofi og prostatakreft
NO994069D0 (no)	1999-08-24	Forbindelser for immunoterapi av prostatacancer og fremgangsmåte for anvendelse derav
NO971015D0 (no)	1997-03-05	Forbindelser og metoder for behandling av cancer
NO984229D0 (no)	1998-09-14	Forbindelser og fremgangsmÕter for immunoterapi og immunodiagnose av prostatakreft
NO20004098D0 (no)	2000-08-16	FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
ATE239509T1 (de)	2003-05-15	Konjugate zur behandlung von prostatakrebs
NO991700D0 (no)	1999-04-09	Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
EP0841940A4 (en)	2005-01-05	METHOD FOR ISOLATING AND / OR PRESERVING DENDRITIC CELLS FOR IMMUNOTHERAPY OF PROSTATE CANCER
NO991955D0 (no)	1999-04-23	FremgangsmÕte for behandling av hydrokarboner
NO20015516D0 (no)	2001-11-12	Preparater og anvendelser av ET743 for behandling av kreft
NO20002189L (no)	2000-06-28	Anvendelse av makrolider for behandling av cancer og mukuladegenerasjon
IS5056A (is)	1999-05-27	Ný meðhöndlun á liðbólgu
NO20012963D0 (no)	2001-06-15	Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
IS5035A (is)	1999-04-27	Aðferðir til varnar gegn brjóstakrabbameini
NO983512D0 (no)	1998-07-30	Midler for behandling og forhindring av AIDS
NO994631D0 (no)	1999-09-23	Fremgangsmaater og sammensetninger for behandling av eggstokkreft
PT984777E (pt)	2004-01-30	Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
ID19542A (id)	1998-07-23	Pengobatan baru
NO20001758D0 (no)	2000-04-05	Fremgangsmåter og blandinger for behandling av leddgikt
ATE250580T1 (de)	2003-10-15	Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
NO961113D0 (no)	1996-03-19	Behandling og forebyggelse av prostatakreft
NO985068D0 (no)	1998-10-30	Vaksiner for behandling av lymfom og leukemi
AU7130696A (en)	1997-04-09	Combination of beta-interferon for the treatment of prostate cancer
NO992561D0 (no)	1999-05-27	Oppslemmingsbehandlingssystem og oppslemmingsbehandlingsmetode
ZA978162B (en)	1998-03-03	Means for treating prostate hypertrophy and prostate cancer.

Legal Events

Date	Code	Title	Description
2011-05-09	MM1K	Lapsed by not paying the annual fees